Evidence map›Paper›PMID 24918167›Full record

GuidelineClinical pharmacology and therapeutics2014

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

L B Ramsey, S G Johnson, K E Caudle, C E Haidar, D Voora, R A Wilke, W D Maxwell, H L McLeod, R M Krauss, D M Roden and 6 more

Registry-linked trialOpen access · bronzeAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05091879 (Implementation and Evaluation of Preemptive Pharmacogenomics Testing in an Aging Population), which is not on this map. Cited by 201 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
201citing papers in PubMed, 8 pooled it
32.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05091879 nacompletednot on this mapstarted 2023, after this paper: background citation

Implementation and Evaluation of Preemptive Pharmacogenomics Testing in an Aging Population

TypeinterventionalSponsorGeisinger ClinicRan2023 to 2026Enrolled66ConditionsPolypharmacy, Pharmacogenomic TestingArmsMultigene pharmacogenomics test
3 · Its place in the literature

Who cites it

201 citing papers in PubMed, 8 syntheses or guidelines pooled it, 439 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy.European journal of clinical pharmacology · 2018 · on this map
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. International journal of molecular medicine · 2026
    Article
  20. Article

141 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 4 countries.

L B RamseyPharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
S G Johnson1] Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, Colorado, USA [2] Clinical Pharmacy Services, Kaiser Permanente Colorado, Denver, Colorado, USA.
K E CaudlePharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
C E HaidarPharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
D VooraDepartment of Medicine, Duke University, Durham, North Carolina, USA.
R A Wilke1] IMAGENETICS, Sanford Medical Center, Fargo, North Dakota, USA [2] Department of Medicine, University of North Dakota, Fargo, North Dakota, USA.
W D MaxwellDepartment of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, Columbia, South Carolina, USA.
H L McLeodPersonalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida, USA.
R M KraussAtherosclerosis Research, Children's Hospital Oakland Research Institute, Oakland, California, USA.
D M Roden1] Oates Institute for Experimental Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA [2] Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
Q Feng1] Oates Institute for Experimental Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA [2] Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
R M Cooper-DeHoffDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA.
L GongDepartment of Genetics, Stanford University, Palo Alto, California, USA.
T E KleinDepartment of Genetics, Stanford University, Palo Alto, California, USA.
M WadeliusDepartment of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
M Niemi1] Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland [2] King Abdulaziz University , Jeddah, Saudi Arabia.
St. Jude Children's Research Hospital · USPalo Alto University · USVanderbilt University · USDuke University · USKing Abdulaziz University · SAMoffitt Cancer Center · USScience for Life Laboratory · SEUniversity of Florida · USUniversity of Montana · USUniversity of North Dakota · US

Funding

PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2M
Pharmacogenomics and Risk of Cardiovascular DiseaseU01HL069757 · NHLBI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI KRAUSS, RONALD M · 2001 to 2009
$24.7M
Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI JOHNSON, JULIE A. · 2005 to 2014
$20.7M
Pharmacogenomics of Arrhythmia TherapyU19HL065962 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 2010 to 2014
$17.4M
Sparking Advancements in Genomic MedicineU01HG007269 · NHGRI · UNIVERSITY OF FLORIDA · PI CAVALLARI, LARISA HUMMA, JOHNSON, JULIE A. · 2013 to 2024
$17.0M
Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) StudyU01HL105198 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHULDINER, ALAN R. · 2010 to 2014
$13.6M
PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9M
Vanderbilt Genome Electronic Records ProjectU01HG006378 · NHGRI · VANDERBILT UNIVERSITY · PI RODEN, DAN M · 2011 to 2014
$4.0M
Development Of Prognostic Platelet RNA Biomarkers To Tailor Antiplatelet TherapyR01HL118049 · NHLBI · DUKE UNIVERSITY · PI VOORA, DEEPAK · 2013 to 2017
$3.9M
NHGRI NIH HHS U01 HG006378NHGRI NIH HHS U01HG006378NHGRI NIH HHS U01 HG007269NHGRI NIH HHS U01HG007269NHLBI NIH HHS R01 HL118049NHLBI NIH HHS U01 HL0105918NHLBI NIH HHS U01 HL069757NHLBI NIH HHS U01HL069757NHLBI NIH HHS U01 HL105198NHLBI NIH HHS U19 HL065962NHLBI NIH HHS U19HL065962NIGMS NIH HHS R24 GM061374NIGMS NIH HHS R24 GM61374NIGMS NIH HHS U01 GM074492NIGMS NIH HHS U01GM074492NIGMS NIH HHS U01 GM092666NIGMS NIH HHS UO1 GM92666
6 · The paper itself

Abstract

Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for simvastatin based on SLCO1B1 genotype. This article is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy.

Indexed as

Drug InteractionsGenotypeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLiver-Specific Organic Anion Transporter 1Muscular DiseasesOrganic Anion TransportersPharmacogeneticsPolymorphism, GeneticSimvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsLiver-Specific Organic Anion Transporter 1Organic Anion TransportersSimvastatinSLCO1B1 protein, human

Identifiers

PMID24918167
PMCPMC4169720
OpenAlexW1968604782

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.